RPL17P2

Across TCGA pan-cancer cohorts, RPL17P2 RNA differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of RPL17P2’s most consistent transcriptional readouts.

The strongest signal is observed in stomach adenocarcinoma (STAD), where RPL17P2 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types RPL17P2 is over-expressed in tumor, although a few such as THCA show the opposite, repressed pattern.

STAD, LUAD, and THCA are the cancer types where RPL17P2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RPL17P2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
STAD	All	IV	+0.266	.006	2	view →
LUAD	All	All	+0.055	.012	2	view →
THCA	All	II,III,IV	−0.027	.039	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 3 strongest of 3 lineages.

RPL17P2–STAD

Open the STAD breakdown →